BioSpace News Archive

The companies are entering an agreement to further enhance their collaboration to meet the requirements of unique military and homeland security customers

Epizyme, Inc. today announced the pricing of two concurrent underwritten public offerings of (i) 10,000,000 shares of its common stock and (ii) 304,348 shares of its non-voting Series A Convertible Preferred Stock.

The SanBio Group today announced its plan to make public the results of a global Phase 2 trial (Study of Modified Stem Cells in Traumatic Brain Injury, or “STEMTRA”) conducted in the US and Japan regarding the use of regenerative cell medicine SB623 as a treatment for chronic motor deficit from traumatic brain injury (TBI).

Glenmark Pharmaceuticals’ new innovation business has its chief executive officer. Alessandro Riva, head of oncology therapeutics and cell therapy at Gilead Sciences will take over the reins of the new innovation company as its CEO on April 2. Riva is the first named executive of the new company.

Bristol-Myers Squibb announced its bid to acquire Celgene on January 3, 2019. However, the deal hit a snag. Bristol-Myers Squibb is now fighting back, making efforts to sell the deal to its shareholders.

Coming off its record-breaking initial public offering (IPO) in December, where it raised $604.3 million, Moderna released its fourth-quarter financials, outlining an ambitious company buzzing with activity.

Janssen believes the treatment works by restoring synaptic connections in brain cells in individuals with major depressive disorder.

This morning, Boston-based Vertex said its triple-combination treatment VX-445, tezacaftor and ivacaftor resulted in statistically significant improvements in lung function in two late-stage cystic fibrosis trials.

Despite releasing positive data on its Phase III ENVISION trial, Alnylam stock dropped 7.5 percent. Although not completely clear why, the drop may be related to a high percentage of serious adverse events observed in the trial.

Beam Therapeutics is one of BioSpace’s NextGen Bio “Class of 2019” Life Science Startups to Watch in 2019.